Literature DB >> 12952225

Intracellular cytokine profiles by peripheral blood CD3+ T-cells in patients with classical Hodgkin lymphoma.

Tryfonia Mainou-Fowler1, Penelope R A Taylor, Sue Miller, Anne M Dickinson, Stephen J Proctor.   

Abstract

The intracellular profiles of T helper type 1 (Th1) and T helper type 2 (Th2) T-cell cytokines by peripheral blood (PB) CD3+ T-cells in patients with classical Hodgkin lymphoma (HL) has not been investigated before. The present study examines the cytoplasmic production of interleukin (IL) 2, 4, 10, tumour necrosis factor alpha (TNFalpha), and interferon gamma (IFNgamma) by activated PB CD3+ T-cells and compares them with the profiles observed with normal individuals. We report a significantly lower mean level of intracellular IL2, TNFalpha and IFNgamma at any time post-cell activation in cells isolated from patients with HL compared with the normal control group. In contrast, the mean level of cytoplasmic IL4 was significantly higher in the HL compared with the control group. No significant difference between the two groups was observed with IL10. In the HL patient group, there was a significantly higher percentage of CD3+CD8+ T-cells that synthesised IL4 compared with the CD3+CD4+ subpopulation, no such difference was observed in normal controls. The intensity of IL4 (expressed as relative median fluorescence) was significantly higher in the CD3+CD8+ cells of the patients with HL compared with the CD3+CD4+ sub-population, or with normal CD3+CD8+ cells. In conclusion, there is reduced intracellular IL2, TNFalpha and IFNgamma and increased cytoplasmic IL4 production by activated PB T-cells in patients with HL. The CD3+CD8+ sub-population is responsible for the increased levels of IL4.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12952225     DOI: 10.1080/1042819031000090246

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  Tumor-released survivin induces a type-2 t cell response and decreases cytotoxic T cell function, in vitro.

Authors:  Jessica M S Jutzy; Salma Khan; Malyn May Asuncion-Valenzuela; Terry-Ann M Milford; Kimberly J Payne; Nathan R Wall
Journal:  Cancer Microenviron       Date:  2012-02-10

2.  T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications.

Authors:  Claudio Fozza; Maurizio Longinotti
Journal:  Adv Hematol       Date:  2010-10-12

3.  Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma.

Authors:  Wendy Cozen; Parkash S Gill; Muhammad T Salam; Alexandra Nieters; Rizwan Masood; Myles G Cockburn; W James Gauderman; Otoniel Martínez-Maza; Bharat N Nathwani; Malcolm C Pike; David J Van Den Berg; Ann S Hamilton; Dennis M Deapen; Thomas M Mack
Journal:  Blood       Date:  2007-12-12       Impact factor: 22.113

Review 4.  Hodgkin lymphoma: an update on its biology with new insights into classification.

Authors:  Haresh Mani; Elaine S Jaffe
Journal:  Clin Lymphoma Myeloma       Date:  2009-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.